Danuglipron (danuglipron)
Pfizer's oral GLP-1. Discontinued in 2025 due to safety concerns.
Danuglipron was Pfizer's investigational oral GLP-1 receptor agonist. Pfizer discontinued development in early 2025 after Phase 2 trials showed liver-enzyme elevations.
Overview
Danuglipron was a small-molecule oral GLP-1 RA — Pfizer's answer to Lilly's orforglipron. After Phase 2 trials showed signals of liver toxicity, Pfizer announced discontinuation in 2025. Pfizer continues development of other obesity drugs in their pipeline.
How Danuglipron Works
Daily oral GLP-1 receptor agonist (small molecule, non-peptide).
Dosing & Schedule
Phase 2 explored once-daily and twice-daily formulations. Specific doses no longer relevant given discontinuation.
Effectiveness — Trial Data
Phase 2: 6-8% weight loss at 26 weeks.
Side Effects
Liver enzyme elevations led to development discontinuation.
Cost — How Much Danuglipron Costs in 2026
Not on market. Will not be developed further.
Who Is Danuglipron For?
No longer applicable.
Danuglipron Alternatives
For oral GLP-1 access: Rybelsus (available), orforglipron (Lilly, expected 2026).